profit from every $100 of sales.
$0$100
SAB Biotherapeutics
$2.96-3.90% today
-4.5% in 1 year
1-year low $2.491-year high $4.59
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $20.09 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What SAB Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with $13.3 million of profit last year.
SalesProfit
SAB Biotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| SAB Biotherapeutics | 20.1× · No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads SAB Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -29 | -38 | -43 | -49 | |
| -15 | -38 | -29 | 17 | |
| -19 | -42 | -34 | 13 | |
| -4.31 | -7.64 | -3.68 | -0.79 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 51 | 84 | 44 | 173 |
| Cash | 15 | 57 | 9 | 11 |
| Total debt | 6 | 6 | 5 | 6 |
| Total liabilities | 20 | 27 | 18 | 21 |
| 31 | 57 | 26 | 151 | |
| 4 | 6 | 9 | 61 | |
| -39.3% | -52.3% | -87.1% | 6.8% | |
| -60.3% | -73.6% | -131.3% | 8.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -23 | -25 | -34 | -45 | |
| 2 | 0 | 0 | 1 | |
| -26 | -25 | -35 | -46 | |
| Dividends paid | – | – | – | – |
| 6 | 0 | – | – | |
| 3 | 2 | 3 | 5 |
Valuation
- 20.1×
- –
- –
- 0.9×
- –
- –
- 13.1×
- -17.1%
- 5.0%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -24.3%
- -51.3%
- -0.3%
- -0.2%
- -24.4%
- –
Growth
- –
- –
- −32.0%
- –
- +45.2%
Financial health
- -8.2×
- 0.03
- 2.5%
- -248.8×
- 11.45
- 11.45
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 963
Bottom 20%of 894
Top 35%of 632
Bottom 4%of 991
What analysts expect
- Average price target
- $7.00
- Range
- $7.00 – $7.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.35 | -0.20 | −75.0% |
| Mar 9, 2026 | -0.46 | -0.16 | −187.5% |
| Nov 14, 2025 | -0.21 | -0.59 | +64.4% |
| Aug 7, 2025 | -1.09 | -0.82 | −32.9% |
| May 9, 2025 | -0.56 | -1.00 | +44.0% |
| Mar 28, 2025 | -1.23 | -1.16 | −6.0% |
| Nov 6, 2024 | -1.12 | -1.07 | −4.7% |
| Aug 8, 2024 | -0.79 | -1.13 | +30.1% |
News
Protalix BioTherapeutics beats top-line and bottom-line estimates; reaffirms FY26 outlookSeeking Alpha · Nov 10, 2026Quant snapshot: Iovance Biotherapeutics and DiamondRock Hospitality Company lead top-rated names as Intact Financial and Fiserv Payments lagSeeking Alpha · Nov 2, 2026Arcutis Biotherapeutics advances 11% to new 52-week highSeeking Alpha · Oct 19, 2026Why Iovance Biotherapeutics Stock Was on Fire TodayYahoo Finance · Sep 25, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
68Pass
Philip Fisher
34No pass
Peter Lynch
60Pass
Joel Greenblatt
11No pass
Charlie Munger
25No pass
Terry Smith
19No pass
Questions about SAB Biotherapeutics
Is SAB Biotherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the SAB Biotherapeutics AI analysis
What does SAB Biotherapeutics do?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It is in Biotechnology.
Does SAB Biotherapeutics pay a dividend?
No. SAB Biotherapeutics does not pay a dividend at the moment.
Is SAB Biotherapeutics stock halal?
Questionable. SAB Biotherapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has SAB Biotherapeutics stock done over the past year?
Down 4.5% over the past twelve months, to $2.96. It traded between $2.49 and $4.59 and is 35.5% below its high.
Who are SAB Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with SAB Biotherapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.